• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RISK-PCI评分对ST段抬高型心肌梗死直接经皮冠状动脉介入治疗患者支架内血栓形成的预测价值:RISK-PCI试验的一项子研究

Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial.

作者信息

Mrdovic Igor, Savic Lidija, Lasica Ratko, Krljanac Gordana, Asanin Milika, Brdar Natasa, Djuricic Nemanja, Cvetinovic Natasa, Marinkovic Jelena, Perunicic Jovan

机构信息

University of Belgrade, School of Medicine, Pasterova 2, 11000, Belgrade, Serbia.

出版信息

Heart Vessels. 2013 Jul;28(4):424-33. doi: 10.1007/s00380-012-0276-z. Epub 2012 Sep 14.

DOI:10.1007/s00380-012-0276-z
PMID:22975713
Abstract

Stent thrombosis (ST) is an important cause of death after primary percutaneous coronary intervention (pPCI). This substudy aimed at evaluating the usefulness of the RISK-PCI score, originally developed for the prediction of 30-day major adverse cardiovascular events, to predict the occurrence of ST after pPCI. We analyzed 1972 consecutive patients who underwent pPCI with stent implantation between February 2007 and December 2009. Early ST (EST), late ST (LST), and cumulative 1-year ST (CST) were the predefined end points. Definite, probable, and possible ST were included. Models discrimination and calibration to predict ST was tested using receiver-operating characteristics curves and the goodness-of-fit (GoF) test. Sensitivity analyses and 1000-resample bootstrapping were used to evaluate the model's performance. The rates of EST, LST, and CST were 4.6, 1.4, and 6.0 %, respectively. Compared with controls, the cumulative ST group was associated with much higher rates of adverse clinical outcomes at 30-day follow-up (adjusted odds ratio (OR) for death 6.45, adjusted OR for major bleeding 4.41) and at 12-month follow-up (adjusted OR for death 7.35, adjusted OR for major bleeding 4.56). Internal validation confirmed a reasonably good discrimination and calibration of the RISK-PCI score for the prediction of EST (area under the curve (AUC) 0.71, GoF 0.42), LST (AUC 0.69, GoF 0.36), and CST (AUC 0.70, GoF 0.22) after pPCI. ST after pPCI is associated with adverse 30-day and 1-year clinical outcomes. We conclude that the risk of ST could be accurately assessed using the RISK-PCI score, which might help in deciding upon measures aimed at preventing adverse prognosis.

摘要

支架血栓形成(ST)是直接经皮冠状动脉介入治疗(pPCI)后导致死亡的重要原因。本亚研究旨在评估最初用于预测30天主要不良心血管事件的RISK-PCI评分对预测pPCI后ST发生的有效性。我们分析了2007年2月至2009年12月期间连续接受pPCI并植入支架的1972例患者。早期ST(EST)、晚期ST(LST)和累积1年ST(CST)为预先设定的终点。包括明确的、很可能的和可能的ST。使用受试者工作特征曲线和拟合优度(GoF)检验来测试预测ST的模型辨别力和校准度。采用敏感性分析和1000次重采样自助法评估模型性能。EST、LST和CST的发生率分别为4.6%、1.4%和6.0%。与对照组相比,累积ST组在30天随访时不良临床结局发生率更高(死亡调整比值比(OR)为6.45,大出血调整OR为4.41),在12个月随访时也是如此(死亡调整OR为7.35,大出血调整OR为4.56)。内部验证证实,RISK-PCI评分对pPCI后EST(曲线下面积(AUC)为0.71,GoF为0.42)、LST(AUC为0.69,GoF为0.36)和CST(AUC为0.70, GoF为0.22)的预测具有较好的辨别力和校准度。pPCI后的ST与30天和1年不良临床结局相关。我们得出结论,使用RISK-PCI评分可以准确评估ST风险,这可能有助于决定采取预防不良预后的措施。

相似文献

1
Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial.RISK-PCI评分对ST段抬高型心肌梗死直接经皮冠状动脉介入治疗患者支架内血栓形成的预测价值:RISK-PCI试验的一项子研究
Heart Vessels. 2013 Jul;28(4):424-33. doi: 10.1007/s00380-012-0276-z. Epub 2012 Sep 14.
2
SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: an ACUITY trial substudy.非ST段抬高型急性冠脉综合征患者经皮冠状动脉介入治疗后SYNTAX评分与支架内血栓形成风险:一项急性冠状动脉治疗和血管造影评价(ACUITY)试验的子研究
Catheter Cardiovasc Interv. 2015 Jan 1;85(1):1-10. doi: 10.1002/ccd.25396. Epub 2014 Jun 17.
3
Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes?: A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials.急性冠状动脉综合征经皮冠状动脉介入治疗中,哪些术中血栓形成事件会影响临床结局?:HORIZONS-AMI和ACUITY试验的汇总分析。
JACC Cardiovasc Interv. 2016 Feb 22;9(4):331-337. doi: 10.1016/j.jcin.2015.10.049. Epub 2016 Jan 20.
4
Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes.术中支架内血栓形成:急性冠脉综合征行经皮冠状动脉介入治疗患者不良结局的一个新的危险因素。
JACC Cardiovasc Interv. 2013 Jan;6(1):36-43. doi: 10.1016/j.jcin.2012.08.018. Epub 2012 Dec 19.
5
Differential 1-year clinical outcomes for ST-segment elevation myocardial infarction related to stent thrombosis or saphenous vein graft thrombosis.ST 段抬高型心肌梗死相关支架血栓形成或隐静脉桥血栓形成的 1 年临床预后差异。
Catheter Cardiovasc Interv. 2013 Aug 1;82(2):193-200. doi: 10.1002/ccd.23300. Epub 2013 May 7.
6
The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.基于解剖和临床的 NERS(新风险分层)评分 II 预测无保护左主干冠状动脉疾病支架置入后的临床结局:来自多中心、前瞻性登记研究的结果。
JACC Cardiovasc Interv. 2013 Dec;6(12):1233-41. doi: 10.1016/j.jcin.2013.08.006. Epub 2013 Nov 13.
7
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.与含有不可降解聚合物的西罗莫司洗脱支架相比,含可生物降解聚合物的比伐卢定洗脱支架在冠状动脉疾病患者中具有更好的安全性和降低支架血栓形成的风险:LEADERS(雷帕霉素从不可降解到可降解涂层支架洗脱)随机、非劣效性试验的最终 5 年报告。
JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011.
8
Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention.支架代际对行罪犯血管血运重建或多支血管血运重建的多支血管病变 ST 段抬高型心肌梗死患者 2 年临床结局的影响。
Catheter Cardiovasc Interv. 2020 Feb;95(2):E40-E55. doi: 10.1002/ccd.28440. Epub 2019 Aug 18.
9
Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).生物可吸收血管支架与依维莫司洗脱金属支架治疗 ST 段抬高型心肌梗死:倾向评分匹配比较的 1 年结果:BVS-EXAMINATION 研究(生物可吸收血管支架——依维莫司洗脱冠状动脉支架治疗 ST 段抬高型心肌梗死患者的临床评估)。
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197. doi: 10.1016/j.jcin.2014.10.005.
10
Predictive value of admission platelet volume indices for in-hospital major adverse cardiovascular events in acute ST-segment elevation myocardial infarction.入院血小板体积指数对急性 ST 段抬高型心肌梗死患者住院期间主要不良心血管事件的预测价值。
Angiology. 2015 Feb;66(2):155-62. doi: 10.1177/0003319713513493. Epub 2013 Dec 3.

引用本文的文献

1
Prognostic Value of the RISK-PCI Score in Patients with Non-ST-Segment Elevation Acute Myocardial Infarction.风险-PCI评分在非ST段抬高型急性心肌梗死患者中的预后价值
J Clin Med. 2025 Apr 16;14(8):2727. doi: 10.3390/jcm14082727.
2
Stent thrombosis in acute coronary syndromes: Patient-related factors and operator-related factors.急性冠脉综合征中的支架血栓形成:患者相关因素和术者相关因素。
Anatol J Cardiol. 2020 Oct;24(4):274-279. doi: 10.14744/AnatolJCardiol.2020.69679.
3
Using the RISK-PCI Score in the Long-Term Prediction of Major Adverse Cardiovascular Events and Mortality after Primary Percutaneous Coronary Intervention.

本文引用的文献

1
Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial.MISSION! 干预研究的 5 年临床随访:ST 段抬高型心肌梗死患者中,西罗莫司洗脱支架与裸金属支架置入的随机对照试验。
EuroIntervention. 2012 Jan;7(9):1021-9. doi: 10.4244/EIJV7I9A164.
2
Assessment of optimum stent deployment by stent boost imaging: comparison with intravascular ultrasound.通过支架增强成像评估最佳支架置入:与血管内超声的比较。
Heart Vessels. 2013 Jan;28(1):1-6. doi: 10.1007/s00380-011-0202-9. Epub 2011 Oct 29.
3
采用 RISK-PCI 评分对初次经皮冠状动脉介入治疗后的主要不良心血管事件和死亡率进行长期预测。
J Interv Cardiol. 2019 Oct 24;2019:2679791. doi: 10.1155/2019/2679791. eCollection 2019.
4
A traditional Chinese medicine therapy for coronary heart disease after percutaneous coronary intervention: a meta-analysis of randomized, double-blind, placebo-controlled trials.经皮冠状动脉介入治疗后冠心病的中医药疗法:一项随机、双盲、安慰剂对照试验的荟萃分析。
Biosci Rep. 2018 Oct 17;38(5). doi: 10.1042/BSR20180973. Print 2018 Oct 31.
5
Antiplatelet Therapy in Percutaneous Coronary Intervention.经皮冠状动脉介入治疗中的抗血小板治疗
Interv Cardiol Clin. 2016 Apr;5(2):221-237. doi: 10.1016/j.iccl.2015.12.007. Epub 2016 Feb 13.
6
JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.JAK2突变与急性冠状动脉综合征合并支架内血栓形成
Heart Vessels. 2016 Oct;31(10):1714-6. doi: 10.1007/s00380-016-0798-x. Epub 2016 Jan 29.
7
Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.急性心肌梗死急性期植入依维莫司洗脱生物可吸收支架的新生内膜覆盖情况及晚期贴壁情况:来自PRAGUE-19研究的光学相干断层扫描数据
Heart Vessels. 2016 Jun;31(6):841-5. doi: 10.1007/s00380-015-0679-8. Epub 2015 Apr 21.
8
Comparison of long-term clinical outcomes between sirolimus- and paclitaxel-eluting stents in real-world clinical practice.西罗莫司洗脱支架与紫杉醇洗脱支架在真实世界临床实践中的长期临床结局比较。
Heart Vessels. 2015 Nov;30(6):746-51. doi: 10.1007/s00380-014-0560-1. Epub 2014 Aug 13.
9
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.经皮冠状动脉介入治疗冠状动脉分叉病变后三联与双联抗血小板治疗:COBIS(冠状动脉分叉支架)II注册研究结果
Heart Vessels. 2015 Jul;30(4):458-68. doi: 10.1007/s00380-014-0500-0. Epub 2014 Mar 30.
10
Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis.经皮冠状动脉介入治疗的冠心病患者三联抗血小板治疗与双联抗血小板治疗的Meta分析
Exp Ther Med. 2013 Oct;6(4):1034-1040. doi: 10.3892/etm.2013.1238. Epub 2013 Jul 30.
Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score.
预测经皮冠状动脉介入治疗后 30 天内主要不良心血管事件。风险 PCI 评分。
Int J Cardiol. 2013 Jan 20;162(3):220-7. doi: 10.1016/j.ijcard.2011.05.071. Epub 2011 Jun 12.
4
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.急性心肌梗死后经皮冠状动脉介入治疗后支架血栓形成的频率及预测因素。
Circulation. 2011 Apr 26;123(16):1745-56. doi: 10.1161/CIRCULATIONAHA.110.981688. Epub 2011 Apr 11.
5
Primary percutaneous coronary intervention and risk of stent thrombosis: a look beyond the HORIZON.
Circulation. 2011 Apr 26;123(16):1709-12. doi: 10.1161/CIRCULATIONAHA.111.023366. Epub 2011 Apr 11.
6
Effect of intravascular ultrasound-guided adjuvant high-pressure non-compliant balloon post-dilation after drug-eluting stent implantation.药物洗脱支架植入术后血管内超声引导下辅助高压非顺应性球囊后扩张的效果
Heart Vessels. 2011 Nov;26(6):565-71. doi: 10.1007/s00380-010-0094-0. Epub 2010 Dec 23.
7
Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry.瑞典的支架血栓形成:来自瑞典冠状动脉造影及血管成形术登记处的报告。
Circ Cardiovasc Interv. 2009 Oct;2(5):401-8. doi: 10.1161/CIRCINTERVENTIONS.108.844985. Epub 2009 Sep 8.
8
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.替格瑞洛与氯吡格雷用于急性冠脉综合征患者的比较
N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
9
Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: rationale and design of the RISK-PCI study.在预先使用 600mg 氯吡格雷治疗的患者中,经皮冠状动脉介入治疗后净不良心血管结局的风险评分模型的开发和验证:RISK-PCI 研究的原理和设计。
J Interv Cardiol. 2009 Aug;22(4):320-8. doi: 10.1111/j.1540-8183.2009.00476.x. Epub 2009 Jun 8.
10
Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention.经皮冠状动脉介入治疗术后 TIMI 血流对心原性休克患者的临床意义。
JACC Cardiovasc Interv. 2009 Jan;2(1):56-64. doi: 10.1016/j.jcin.2008.10.006.